Details of the Drug

General Information of Drug (ID: DMB19L8)

Drug Name
Trihexyphenidyl
Synonyms
trihexyphenidyl; Benzhexol; Triphenidyl; Trihexyphenidyle; Parkinane retard; Benzhexolum; 144-11-6; Trihexyphenidylum; Sedrena (free base); Trihexifenidilo; Trihexyphenidyle [INN-French]; Trihexifenidilo [INN-Spanish]; Trihexyphenidylum [INN-Latin]; Artane; Trihexylphenizyl; Trihexylphenidyl; Trihexylphenidyle; Trihexyphenidyl [INN:BAN]; Trihexylphenedyl; HSDB 3196; EINECS 205-614-4; NSC 12268; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; BRN 0088959; Benzhexol; Trihexane; Trihexy; Artane Sequels; PMS Trihexyphenidyl; Apo-Trihex; Artane (TN); Trihexyphenidyl (INN); Apo-Trihex (TN); Apo-trihex (TN); SWR-0342SA
Indication
Disease Entry ICD 11 Status REF
Dystonia 8A02 Approved [1], [2], [3]
Parkinson disease 8A00.0 Approved [1], [2], [3]
Obesity 5B81 Investigative [4]
Therapeutic Class
Antiparkinson Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 301.5
Topological Polar Surface Area (xlogp) 4.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 201 mcgh/L [5]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 7.2 mcg/L [5]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.3 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.2 +/- 0.3 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.6341 micromolar/kg/day [8]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [6]
Chemical Identifiers
Formula
C20H31NO
IUPAC Name
1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
Canonical SMILES
C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
InChI
InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2
InChIKey
HWHLPVGTWGOCJO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5572
ChEBI ID
CHEBI:9720
CAS Number
144-11-6
DrugBank ID
DB00376
TTD ID
D09GFL
VARIDT ID
DR00982
INTEDE ID
DR2309
ACDINA ID
D00704

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-3 (ADRB3) TTMXGCW ADRB3_HUMAN Agonist [4]
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Antagonist [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Dystonia
ICD Disease Classification 8A02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Muscarinic acetylcholine receptor M1 (CHRM1) DTT CHRM1 5.59E-01 0.19 0.41
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Trihexyphenidyl (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Trihexyphenidyl when combined with Bethanechol. Abnormal micturition [MF50] [29]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Oliceridine. Acute pain [MG31] [30]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Scopolamine. Addictive disorder [6C50-6C5Z] [31]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [32]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [31]
Tacrine DM51FY6 Moderate Antagonize the effect of Trihexyphenidyl when combined with Tacrine. Alzheimer disease [8A20] [33]
Donepezil DMIYG7Z Moderate Antagonize the effect of Trihexyphenidyl when combined with Donepezil. Alzheimer disease [8A20] [33]
Marinol DM70IK5 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Marinol. Anorexia nervosa [6B80] [30]
Methylphenobarbital DMDSWAG Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [30]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [31]
Promazine DMZAL7W Moderate Antagonize the effect of Trihexyphenidyl when combined with Promazine. Appearance/behaviour symptom [MB23] [34]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Desipramine. Attention deficit hyperactivity disorder [6A05] [31]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Cariprazine. Bipolar disorder [6A60] [31]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Trihexyphenidyl and Loperamide. Bowel habit change [ME05] [35]
Sotalol DML60TN Moderate Antagonize the effect of Trihexyphenidyl when combined with Sotalol. Cardiac arrhythmia [BC9Z] [36]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Trihexyphenidyl when combined with Acetylcholine. Cataract [9B10] [37]
Secobarbital DM14RF5 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Secobarbital. Chronic insomnia [7A00] [30]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [38]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Tiotropium. Chronic obstructive pulmonary disease [CA22] [38]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Revefenacin. Chronic obstructive pulmonary disease [CA22] [38]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Dihydrocodeine. Chronic pain [MG30] [30]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Olopatadine. Conjunctiva disorder [9A60] [39]
Methohexital DM7YMIT Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Methohexital. Corneal disease [9A76-9A78] [30]
Thiopental DMGP8AX Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Thiopental. Corneal disease [9A76-9A78] [30]
Alfentanil DMVO0UB Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Alfentanil. Corneal disease [9A76-9A78] [30]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Remifentanil. Corneal disease [9A76-9A78] [30]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Trihexyphenidyl and Arbutamine. Coronary atherosclerosis [BA80] [40]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Ethanol. Cystitis [GC00] [41]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Trimipramine. Depression [6A70-6A7Z] [31]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Cyclobenzaprine. Depression [6A70-6A7Z] [31]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Imipramine. Depression [6A70-6A7Z] [31]
Isocarboxazid DMAF1NB Minor Additive anticholinergic effects by the combination of Trihexyphenidyl and Isocarboxazid. Depression [6A70-6A7Z] [30]
Tranylcypromine DMGB5RE Minor Additive anticholinergic effects by the combination of Trihexyphenidyl and Tranylcypromine. Depression [6A70-6A7Z] [30]
OPC-34712 DMHG57U Moderate Antagonize the effect of Trihexyphenidyl when combined with OPC-34712. Depression [6A70-6A7Z] [34]
Phenelzine DMHIDUE Minor Additive anticholinergic effects by the combination of Trihexyphenidyl and Phenelzine. Depression [6A70-6A7Z] [30]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Clomipramine. Depression [6A70-6A7Z] [31]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Amoxapine. Depression [6A70-6A7Z] [31]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Doxepin. Depression [6A70-6A7Z] [31]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Maprotiline. Depression [6A70-6A7Z] [31]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Esketamine. Depression [6A70-6A7Z] [42]
Nitroglycerin DMQ2491 Minor Decreased dissolution of Trihexyphenidyl taken sublingually caused by Nitroglycerin. Diabetic foot ulcer [BD54] [43]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Hyoscyamine. Digestive system disease [DE2Z] [31]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Oxybutynine. Discovery agent [N.A.] [31]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [30]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Trihexyphenidyl and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [44]
Primidone DM0WX6I Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Primidone. Epilepsy/seizure [8A61-8A6Z] [30]
Phenobarbital DMXZOCG Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [30]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Cannabidiol. Epileptic encephalopathy [8A62] [30]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Diphenhydramine. Episodic vestibular syndrome [AB31] [31]
Bendroflumethiazide DM7EVLC Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Bendroflumethiazide. Essential hypertension [BA00] [45]
Benzthiazide DMQWZ0H Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Benzthiazide. Essential hypertension [BA00] [45]
Nadolol DMW6GVL Moderate Antagonize the effect of Trihexyphenidyl when combined with Nadolol. Essential hypertension [BA00] [36]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Solifenacin. Functional bladder disorder [GC50] [31]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Tolterodine. Functional bladder disorder [GC50] [31]
Darifenacin DMWXLYZ Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Darifenacin. Functional bladder disorder [GC50] [31]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Trihexyphenidyl due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [46]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Propantheline. Gastric ulcer [DA60] [31]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Trihexyphenidyl when combined with Isoflurophate. Glaucoma [9C61] [37]
Carteolol DMFMDOB Moderate Antagonize the effect of Trihexyphenidyl when combined with Carteolol. Glaucoma [9C61] [36]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Brimonidine. Glaucoma [9C61] [47]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Trihexyphenidyl when combined with Pilocarpine. Glaucoma [9C61] [37]
Carvedilol DMHTEAO Moderate Antagonize the effect of Trihexyphenidyl when combined with Carvedilol. Heart failure [BD10-BD1Z] [36]
Chlorothiazide DMLHESP Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [45]
Digoxin DMQCTIH Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Digoxin. Heart failure [BD10-BD1Z] [48]
Hydroflumethiazide DMVPUQI Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Hydroflumethiazide. Heart failure [BD10-BD1Z] [45]
Acebutolol DM0TI4U Moderate Antagonize the effect of Trihexyphenidyl when combined with Acebutolol. Hypertension [BA00-BA04] [36]
Bisoprolol DM3UZ95 Moderate Antagonize the effect of Trihexyphenidyl when combined with Bisoprolol. Hypertension [BA00-BA04] [36]
Penbutolol DM4ES8F Moderate Antagonize the effect of Trihexyphenidyl when combined with Penbutolol. Hypertension [BA00-BA04] [36]
Nebivolol DM7F1PA Moderate Antagonize the effect of Trihexyphenidyl when combined with Nebivolol. Hypertension [BA00-BA04] [36]
Indapamide DMGN1PW Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [45]
Trichlormethiazide DMHAQCO Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [45]
Labetalol DMK8U72 Moderate Antagonize the effect of Trihexyphenidyl when combined with Labetalol. Hypertension [BA00-BA04] [36]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [45]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Amantadine. Influenza [1E30-1E32] [49]
Amobarbital DM0GQ8N Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Amobarbital. Insomnia [7A00-7A0Z] [30]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Propiomazine. Insomnia [7A00-7A0Z] [31]
ITI-007 DMUQ1DO Moderate Antagonize the effect of Trihexyphenidyl when combined with ITI-007. Insomnia [7A00-7A0Z] [34]
Nabilone DMVRYT2 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Nabilone. Insomnia [7A00-7A0Z] [30]
R0-93877 DMM4U9G Moderate Antagonize the effect of Trihexyphenidyl when combined with R0-93877. Irritable bowel syndrome [DD91] [50]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Clidinium. Irritable bowel syndrome [DD91] [31]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Dicyclomine. Irritable bowel syndrome [DD91] [31]
Physostigmine DM2N0TO Moderate Antagonize the effect of Trihexyphenidyl when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [33]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [51]
Propranolol DM79NTF Moderate Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Propranolol. Migraine [8A80] [42]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Lasmiditan. Migraine [8A80] [52]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Flibanserin. Mood disorder [6A60-6E23] [53]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Trihexyphenidyl when combined with Neostigmine. Myasthenia gravis [8C6Y] [54]
Pyridostigmine DM8HO1L Moderate Antagonize the effect of Trihexyphenidyl when combined with Pyridostigmine. Myasthenia gravis [8C6Y] [54]
Edrophonium DMCRQHB Moderate Antagonize the effect of Trihexyphenidyl when combined with Edrophonium. Myasthenia gravis [8C6Y] [54]
Ambenonium DMOP0BL Moderate Antagonize the effect of Trihexyphenidyl when combined with Ambenonium. Myasthenia gravis [8C6Y] [54]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Phenindamine. Nasopharyngitis [CA00] [31]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Dimenhydrinate. Nausea/vomiting [MD90] [31]
Prochlorperazine DM53SRA Moderate Antagonize the effect of Trihexyphenidyl when combined with Prochlorperazine. Nausea/vomiting [MD90] [34]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Promethazine. Nausea/vomiting [MD90] [31]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Cyclizine. Nausea/vomiting [MD90] [31]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Trihexyphenidyl when combined with Metoclopramide. Nausea/vomiting [MD90] [55]
Metolazone DMB39LO Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Metolazone. Oedema [MG29] [45]
Polythiazide DMCH80F Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [45]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Levomethadyl Acetate. Opioid use disorder [6C43] [30]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Apraclonidine. Optic nerve disorder [9C40] [47]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Pentazocine. Pain [MG30-MG3Z] [30]
Dextropropoxyphene DM23HCX Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Dextropropoxyphene. Pain [MG30-MG3Z] [30]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Butorphanol. Pain [MG30-MG3Z] [30]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Oxymorphone. Pain [MG30-MG3Z] [30]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Levorphanol. Pain [MG30-MG3Z] [30]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Dezocine. Pain [MG30-MG3Z] [30]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Flavoxate. Pain [MG30-MG3Z] [31]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Nalbuphine. Pain [MG30-MG3Z] [30]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Buprenorphine. Pain [MG30-MG3Z] [30]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Hydrocodone. Pain [MG30-MG3Z] [30]
Meperidine DMX4GND Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Meperidine. Pain [MG30-MG3Z] [30]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Oxycodone. Pain [MG30-MG3Z] [30]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Biperiden. Parkinsonism [8A00] [31]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Procyclidine. Parkinsonism [8A00] [31]
Levodopa DMN3E57 Moderate Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [56]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Orphenadrine. Parkinsonism [8A00] [31]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Methylscopolamine. Peptic ulcer [DA61] [31]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Levomepromazine. Psychotic disorder [6A20-6A25] [31]
Fluphenazine DMIT8LX Moderate Antagonize the effect of Trihexyphenidyl when combined with Fluphenazine. Psychotic disorder [6A20-6A25] [34]
Triflupromazine DMKFQJP Moderate Antagonize the effect of Trihexyphenidyl when combined with Triflupromazine. Psychotic disorder [6A20-6A25] [34]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Cyproheptadine. Rheumatoid arthritis [FA20] [31]
Quetiapine DM1N62C Moderate Antagonize the effect of Trihexyphenidyl when combined with Quetiapine. Schizophrenia [6A20] [34]
Mesoridazine DM2ZGAN Moderate Antagonize the effect of Trihexyphenidyl when combined with Mesoridazine. Schizophrenia [6A20] [34]
Thioridazine DM35M8J Moderate Antagonize the effect of Trihexyphenidyl when combined with Thioridazine. Schizophrenia [6A20] [34]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Trihexyphenidyl when combined with Aripiprazole. Schizophrenia [6A20] [34]
Iloperidone DM6AUFY Moderate Antagonize the effect of Trihexyphenidyl when combined with Iloperidone. Schizophrenia [6A20] [34]
Paliperidone DM7NPJS Moderate Antagonize the effect of Trihexyphenidyl when combined with Paliperidone. Schizophrenia [6A20] [34]
Loxapine DM8AI9U Moderate Antagonize the effect of Trihexyphenidyl when combined with Loxapine. Schizophrenia [6A20] [34]
Haloperidol DM96SE0 Moderate Antagonize the effect of Trihexyphenidyl when combined with Haloperidol. Schizophrenia [6A20] [34]
Perphenazine DMA4MRX Moderate Antagonize the effect of Trihexyphenidyl when combined with Perphenazine. Schizophrenia [6A20] [34]
Chlorpromazine DMBGZI3 Moderate Antagonize the effect of Trihexyphenidyl when combined with Chlorpromazine. Schizophrenia [6A20] [34]
Thiothixene DMDINC4 Moderate Antagonize the effect of Trihexyphenidyl when combined with Thiothixene. Schizophrenia [6A20] [34]
Trifluoperazine DMKBYWI Moderate Antagonize the effect of Trihexyphenidyl when combined with Trifluoperazine. Schizophrenia [6A20] [34]
Risperidone DMN6DXL Moderate Antagonize the effect of Trihexyphenidyl when combined with Risperidone. Schizophrenia [6A20] [34]
Asenapine DMSQZE2 Moderate Antagonize the effect of Trihexyphenidyl when combined with Asenapine. Schizophrenia [6A20] [34]
Pimozide DMW83TP Moderate Antagonize the effect of Trihexyphenidyl when combined with Pimozide. Schizophrenia [6A20] [34]
Fentanyl DM8WAHT Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Fentanyl. Sensation disturbance [MB40] [30]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Sufentanil. Sensation disturbance [MB40] [30]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Trihexyphenidyl and Tizanidine. Tonus and reflex abnormality [MB47] [57]
Pramlintide DM0EZ9Q Moderate Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [58]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Atropine. Unspecific substance harmful effect [NE6Z] [31]
Nitrofurantoin DM7PQIK Minor Altered absorption of Trihexyphenidyl due to GI dynamics variation caused by Nitrofurantoin. Urinary tract infection [GC08] [59]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [31]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Triprolidine. Vasomotor/allergic rhinitis [CA08] [31]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Methdilazine. Vasomotor/allergic rhinitis [CA08] [31]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [31]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [32]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [31]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [31]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Acrivastine. Vasomotor/allergic rhinitis [CA08] [31]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Trihexyphenidyl and Azatadine. Vasomotor/allergic rhinitis [CA08] [31]
⏷ Show the Full List of 151 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Trihexyphenidyl 2 mg tablet 2 mg Oral Tablet Oral
Trihexyphenidyl 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7315).
2 Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
5 Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol. 1985 Jul;18(1):35-40. doi: 10.1002/ana.410180107.
6 BDDCS applied to over 900 drugs
7 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
10 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
11 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
12 Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
13 Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
14 Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
15 Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
16 Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
17 Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
18 [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11.
19 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
20 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
21 Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
22 Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
23 Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
24 Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
25 Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
27 FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
28 Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.
29 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
30 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
31 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
32 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
33 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
34 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
35 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
36 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37 Multum Information Services, Inc. Expert Review Panel.
38 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
39 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
40 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
41 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
42 Cerner Multum, Inc. "Australian Product Information.".
43 Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
44 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
45 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
46 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
47 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
48 Binnion PF, McDermott M, LeSher D "Bioavailability of digoxin." Lancet 1 (1973): 1118. [PMID: 4122032]
49 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
50 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
51 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
52 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
53 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
54 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
55 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
56 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
57 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
58 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
59 Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]